ECSIT

Across TCGA pan-cancer cohorts, ECSIT mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated ECSIT data layer compared with 23 for mass-spec protein and 5 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher ECSIT mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ECSIT expression acts as an unfavorable survival marker, although some lineages such as LSCC and GBM show a favorable association.

LSCC, GBM, and PDAC are the cancer types where ECSIT mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	II,III,IV	0.858	0.527	.005	31	view →
GBM	OS	Median	All	0.698	0.361	<.001	20	view →
PDAC	OS	Quartile	All	0.329	0.636	.004	14	view →
CCRCC	DFS	Median	II,III,IV	0.810	1.000	.006	11	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

ECSIT–LSCC (DFS)

Open the LSCC breakdown →